|
|
| (11) | Number of the document | C 1532149 |
| (68) | Number of the document | 1532149 |
| (21) | Application number for Supplementary Protection Certificate | PA 2011 013 |
| (22) | Date of filing the application | 2011-10-25 |
| (41) | Date of publication of the application | 2011-11-25 |
| Date of publication of SPC | 2012-08-27 | |
| (24) | Date of coming into effect of SPC | 2023-08-19 |
| (71) |
Boehringer Ingelheim Pharma GmbH & Co. KG,
55216 Ingelheim am Rhein,
DE
|
| (73) |
Boehringer Ingelheim Pharma GmbH & Co. KG,
55216 Ingelheim am Rhein,
DE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (93) | EU/1/11/707/001, 2011-08-24 EU/1/11/707/002, 2011-08-24 EU/1/11/707/003, 2011-08-24 EU/1/11/707/004, 2011-08-24 EU/1/11/707/005, 2011-08-24 EU/1/11/707/006, 2011-08-24 EU/1/11/707/007, 2011-08-24 EU/1/11/707/008, 2011-08-24 EU/1/11/707/009, 2011-08-24 |
| (94) | 2026-08-30 |
| (95) | Linagliptinum |
| Request filed | SPC extension granted until | Request refused | |
| 2024-03-28 | 2027-02-28 |
| Payment date | Validity (years) | Amount | |
| 2025-07-23 | 3 | 347.00 EUR |
| 2026-08-19 |
| SPC term extension granted |